

pharmacogenetics of efavirenz and central nervous system side effects

Can efavirenz be taken in the morning? Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: Long-term neuropsychiatric disorders on efavirenz-based approaches: Safer sex Relationships and feelings
Contraception Sexually transmitted infections. References Gallego L et al. Featured Resources Antiretroviral drugs chart
A one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions. Gynaecomastia enlargement of the breasts has been observed in a small number of people taking efavirenz. Search for HIV services across the world Find contact details for over key organisations in more than countries. Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: Find out the answers in this section. Dec 3, - Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Haas DW(1), Ribaud HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgand T, Marzolini C, Acosta EP. Author information: (1)Program for Human Genetics, Vanderbilt. Efavirenz is an effective antiretroviral agent, but central nervous system side effects occur commonly, and population (racial) differences in pharmacokinetics and response have been reported. Efavirenz is metabolized by cytochrome PB6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4. Dec 3, - Objectives: Efavirenz is an effective antiretroviral agent, but central nervous system side effects occur commonly, and population (racial) differences in pharmacokinetics and response have been reported. Efavirenz is metabolized by cytochrome PB6 (CYP2B6). We investigated whether polymorphisms. Jun 9, - Pharmacogenetics of Efavirenz. Discontinuation for Central. Nervous System Symptoms Central nervous system (CNS) symptoms affect % of patients, and cause treatment discontinuation in about 5%. EFV side effects and discontinuation. 4. To explore associations between smoking, genetics. Feb 1, - Efavirenz is metabolized primarily by cytochrome P (CYP) 2B6, with some involvement of CYP3A [9]. A G-to-T polymorphism at position of CYP2B6 is associated with higher plasma efavirenz concentrations and slower plasma efavirenz clearance, as well as increased CNS-related side effects [10]. Jul 6, - These previous studies, together with the present study, suggest that among patients with intermediate or slow metabolizer genotypes who are prescribed efavirenz in the United States, central nervous system side effects, including suicidality, are more likely to be reported among white than among black. of CNS-related side effects. Although genetic screening of patients about to initiate therapy with efavirenz is not considered cost-effective, pharmacogenetic analysis in specific cases has proven very useful in determining the right efavirenz dosage for achieving and maintaining a therapeutic plasma concentration In fact. This is still a research test, not in general use. Publication Types: Newspaper Article AIDS. Dec 3;18(18) Related Articles, Links Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Haas DW, Ribaud HJ, Kim RB, Tierney C, Wilkinson GR, Gulick. This study aimed to identify the G>T polymorphism of the CYP2B6 gene and evaluate its influence on central nervous system (CNS) side effect development in HIV-positive individuals undergoing Efavirenz. (EFV) treatment in a population from southern Brazil. Additionally, we performed a survey on the clinical. These three studies strongly suggest that, among patients with slow metabolizer genotypes who are prescribed efavirenz in the United States, central nervous system side effects are substantially less likely to be reported among Blacks than among Whites, this despite strong evidence that plasma efavirenz exposure is very.